Related Experiment Video
Updated: Jun 9, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
[Treatment goals in pulmonary arterial hypertension]
Laurent Savale1, Olivier Sitbon
1Université Paris-Sud XI, Faculté de Médecine, Le Kremlin-Bicêtre, France. olivier.sitbon@abc.aphp.fr
Abstract:
A goal-oriented treatment strategy is recommended in patients with pulmonary arterial hypertension (PAH). The current treatment goals are based on regular assessment of clinical parameters that have been demonstrated as prognostic factors at the time of initial evaluation. The prognostic value of the course of these parameters assessed at follow-up on PAH-specific therapies is unknown. The aim of the EFORT clinical study is to analyse the prognostic factors assessed at follow-up in patients with PAH, to provide more accurate information in terms of treatment goals than the simple analysis of prognostic factors at baseline. This clinical research project should help to establish new recommendations for the management of patients with PAH. The impact of these new therapeutic approaches on long-term survival of patients with PAH is a major challenge in the near future.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

